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Dengue virus infection can lead to dengue fever (DF) or dengue hemorrhagic fever (DHF). Disease severity has been linked to
an increase in various cytokine levels. In this study, we evaluated the eﬀectiveness of doxycycline and tetracycline to modulate
serum levels of IL-6, IL-1B, and TNF and cytokine receptor/receptor antagonist TNF-R1 and IL-1RA in patients with DF or
DHF. Hospitalized patients were randomized to receive standard supportive care or supportive care combined with doxycycline or
tetracycline therapy. Serum cytokine and cytokine receptor/antagonist levels were determined at the onset of therapy and after 3
and 7 days. Cytokine and cytokine receptor/antagonist levels were substantially elevated at day 0. IL-6, IL-1β, and TNF remained
at or above day 0 levels throughout the study period in untreated patients. Treatment with tetracycline or doxycycline resulted in
a signiﬁcant decline in cytokine levels. Similarly, IL-1RA and TNF-R1 serum concentrations were elevated at baseline and showed
a moderate increase among untreated patients. Both drugs resulted in a signiﬁcant rise in IL-1Ra levels by day 3 in patients. In
contrast, treatment did not aﬀect a similar result for TNF-R1. When compared to the control group, however, a signiﬁcant rise
post-treatment was seen upon intragroup analysis. Further analysis demonstrated that doxycycline was signiﬁcantly more eﬀective
at modulating cytokine and cytokine receptor/antagonist levels than tetracycline.
1.Introduction
Dengue fever (DF) is a mosquito borne disease prevalent
in tropical and subtropical areas of the world caused by 4
serotypes of Flavivirus [1]. The World Health Organization
estimates 50 million cases occur annually in 100 countries
with most patients presenting with ﬂu-like symptoms [2].
Approximately 2.5 percent of those infected develop dengue
hemorrhagic fever (DHF) characterized by prolonged very
high fever, bleeding at mucosal surfaces, and signiﬁcant
hematological abnormalities, which can lead to circulatory
collapse and death in 2.5–20% of cases [1–3]. Unfortunately,
the last 2 decades have seen a marked increase in geograph-
ical distribution and signiﬁcant outbreaks of both DF and
DHF [2]. There is no vaccine against, or speciﬁc treatment
for, either disease entity other than general supportive care.
What determines if infection leads to DF or DHF is not
well understood, but prior exposure to dengue virus may
p l a yac r i t i c a lr o l e[ 2]. Cytokines are known to play a role
in several viral hemorrhagic fevers including dengue [4, 5].
Previous studies have shown a correlation between increased
levels of several cytokines and disease severity which may
have prognostic value [5–8]. In general, these studies have
shownthatlevelsofcytokinesadverselyaﬀectingcoagulation
tended to be higher in DHF versus DF [9, 10].
Given the critical role of cytokines in the inﬂammatory
process and coagulopathies, there have been numerous
attempts to suppress their levels in an attempt to control
various diseases [11–13]. Various classes of antibiotics have
been shown to possess immunomodulating properties [14].
Of these, drugs belonging to the tetracycline family were
found to beneﬁt patients with multiple sclerosis, Hunt-
ington’s disease and rheumatoid arthritis presumably by
suppressingmicrogliaactivity[14–18].This,inturn,lowered
levels of several proinﬂammatory cytokines including tissue
necrosisfactor(TNF)andinterleukin1beta(IL-1β)[14,18].2 Clinical and Developmental Immunology
Recently, the levels of several proinﬂammatory cytokines
in patients with tick-borne encephalitis (TBE) treated with
tetracycline were found to be signiﬁcantly lower than in un-
treated controls [5].
The present study was conducted to evaluate the abil-
ity of tetracycline and doxycycline to modulate cytokines
and cytokine soluble receptors and receptor antagonists in
patients with DF or DHF.
2.MaterialsandMethods
2.1. Subjects. The study protocol was approved by the Inde-
pendent University of Yucatan, Merida, Yucatan, Mexico.
Informed consent was obtained from all adult patients and
from the parents of children. Patients (34 untreated controls,
45 which received Doxycycline, and 35 which received
tetracycline, see below) were recruited between June and
December 2009 from hospitals in rural Latin America.
Blood samples were obtained from hospitalized patients
8–55 years of age presenting with symptoms characteristic
of DF or DHF. For a presumptive diagnosis of DF or DHF
(Day 0), a fever for more than 2 days accompanied by
two or more of the following were present severe headache,
retro-orbital pain, myalgia, arthralgia, rash, leucopenia,
and hemorrhage. Serum was collected, and dengue virus
infection was conﬁrmed by PCR testing. DHF was deﬁned
as being PCR-positive for dengue virus accompanied by
fever with one or more of the following being present
positive tourniquet test for petechiae, mucosal hemorrhage,
thrombocytopenia, an increase of >20% in hematocrit, or
clinical evidence of shock. Patients were randomized within
72 hours of a conﬁrmed diagnosis. All patients received
symptomatic and supportive care as required. Doxycycline
(Vibramycin, Pﬁzer, N.Y., USA) was administered as follows.
For patients 18–55 years of age, an initial oral dose of 200mg
was followed by 100mg administered at 12 hour intervals
for 10 days. The same dosing regimen was used for patients
15–17 years of age, but only for 7 days. For those 8–14 years
old, a single day 1 loading dose of 4mg/kg/day was followed
by 4/mg/kg/day divided between two doses given 12 hours
apart for 7 days. Tetracycline (Tetrex, Hormona SA de C.V.,
Edo de Mexico, Mexico) was given as follows. In patients 18–
55 years of age, 500mg were administered orally at 8 hour
intervals for 10 days. For those 15–17 years old, 500mg were
administered at 12 hour intervals for 7 days. Patients 8–14
years of age received 50mg/kg/day divided between 3 doses
given 8 hours apart for 7 days.
2.2. Diagnostic Tests. Infection with dengue virus was con-
ﬁrmed by PCR using multiple primers.
2.3.CytokineAssays. Bloodsampleswereprocessedtoobtain
serum which was stored at −70
◦C. Assays were performed
in a blinded manner after all samples were collected. Serum
cytokine and cytokine receptor levels were quantiﬁed using
commercial ELISA tests kits (R & D Systems, Minneapolis,
MN, USA) per the manufacturer’s instructions. The limits
of detection are as follows: IL (interleukin)-6, 0.7pg/mL; IL-
1β,<1pg/mL; IL-1receptorantagonist)(IL-1RA),14pg/mL;
TNF, 0.6pg/mL; and soluble TNF receptor (sTNF-R1),
3pg/mL.
2.4. Statistical Analysis. Statistical analysis comparing cy-
tokine and cytokine receptor/antagonist levels between con-
trols (untreated) and treatment groups (intergroup analysis)
was performed using the unpaired Student t-test. Data was
adjusted for day zero values for each patient. Intragroup
analysis (comparing day 0 versus day 3 and day 7 within the
same group) was done using a paired Students t-test. A P
value < .05 was considered statistically signiﬁcant.
3. Results
3.1. Eﬀect of Doxycycline and Tetracycline Treatment on Serum
Cytokine and Cytokine Receptor/Antagonist Levels in Patients
with DF. All patients demonstrated elevated cytokine and
cytokine receptor/antagonist levels at day 0 evidenced by
higher mean levels in all study groups (Table 1). Over
the 7-day observation period, proinﬂammatory cytokine
(IL-6, IL-1β, and TNF) remained elevated in the control
group. Similarly, IL1-RA and sTNF-R1 concentrations also
remained elevated over the observation period. Treatment
with doxycycline resulted in statistically (P<. 01) lower
levels of proinﬂammatory cytokines by day 3, both when
compared to that seen at day 0 (intragroup analysis) and
when compared to day 0 values in the control group. This
decline continued with day 7 values signiﬁcantly (P<. 01)
lower than those seen on day 3 (both inter- and intragroup).
Treatment with tetracycline resulted in a similar trend, but
generally it was not as rapid or pronounced. IL1-RA and
TNF-R1 (molecules which downregulate cytokine activities)
were found to be well above that seen in healthy individuals
at time 0 in all patients. Increases between day 0 and
day 7 values were modest in the control group. Treatment
with doxycycline or tetracycline resulted in IL1-RA levels
being signiﬁcantly higher by day 3 and day 7, respectively.
TNF-R1 levels were not signiﬁcantly diﬀerent between
untreated patients and those receiving either tetracycline or
doxycycline. Intragroup analysis comparing day 0 with day 3
and day 7 values demonstrated that both IL1-RA and TNF-
R1 levels were signiﬁcantly higher in all groups.
3.2. Eﬀect of Doxycycline and Tetracycline Treatment on
Serum Cytokine and Cytokine Receptor/Antagonist Levels in
Patients with DHF. Doxycycline and tetracycline were also
found to be eﬀective at modulating cytokine and cytokine
receptor/antagonist levels in patients with DHF (Table 2).
Cytokine (IL-6, IL-1β, and TNF) levels were elevated in
all groups at day 0 and remained so in untreated patients
through day 7 (Table 2). Treatment with either doxycycline
or tetracycline resulted in a signiﬁcant (P<. 01) reduction
in cytokine levels by day 3 posttreatment when compared
to either day 0 values in the control group or intragroup
day 0 levels. This decline continued through day 7. Control
patients with DHF also displayed a modest (15–30%) butClinical and Developmental Immunology 3
Table 1: Eﬀect of Doxycycline and Tetracycline on cytokine levels and IL1-RA and S TNF-R1 in patients with dengue fever.
Treatment group (GMT and ranges, pg/mL)
Control Doxycycline Tetracycline
Day 0 Day 3 Day 7 Day 0 Day 3 Day 7 Day 0 Day 3 Day 7
IL-6 6.99 7.58 7.41 7.47 5.98
∗ 3.96
∗ 7.38 6.36
∗ 5.48
∗
(5.59–8.32) (6.24–8.98) (4.18–9.30) (6.28–9.16) (3.70–7.98) (2.32–6.89) (5.33–9.39) (4.72–7.90) (3.89–7.07)
IL-1β 4.53 4.95 4.64 4.53 2.29
∗ 1.55
∗ 4.41 3.36
∗ 2.23
∗
(3.32–6.30) (3.67–6.54) (2.25–6.43) (3.35–6.36) (1.23–4.12) (1.10–2.78) (3.15–6.27) (1.48–5.43) (1.02–4.69)
IL1 RA 325 344 349 264 673
∗ 964
∗ 263 330
∗ 404
∗
(189–632) (202–714) (199–699) (187–381) (486–851) (701–1459) (184–366) (201–732) (231–920)
TNF 4.38 5.02 5.20 4.46 2.42
∗ 0.90
∗ 4.37 3.89
∗ 3.31
∗
(2.69–6.43) (2.85–7.89) (3.10–8.21) (2.66–6.54) (0.23–4.63) (0.4–3.02) (2.67–6.22) (2.03–5.65) (1.19–5.08)
TNF R1 1751 2074 2189 1969 2432
† 2616
† 1816 2115
† 2324
†
(989–2899) (1143–3304) (1200–3278) (298–3312) (673–3762) (1021–4412) (1099–2766) (1358–3282) (1409–3974)
∗(P<. 01).
†(P>. 05).
Table 2: Eﬀect of Doxycycline and Tetracycline on cytokine levels and IL1-RA and S TNF-R1 in patients with dengue hemorrhagic fever.
Treatment group (GMT and ranges, pg/mL)
Control Doxycycline Tetracycline
Day 0 Day 3 Day 7 Day 0 Day 3 Day 7 Day 0 Day 3 Day 7
IL-6 4.75 5.22 5.20 5.54 3.84
∗ 2.36
∗ 5.11 4.68
∗ 4.23
∗
(3.28–7.24) (3.24–7.89) (3.27–8.04) (3.42–7.65) (2.01–6.73) (1.24–5.38) (3.27–7.28) (2.93–6.98) (2.46–6.66)
IL-1β 6.88 7.83 8.07 7.56 5.32
∗ 3.29
∗ 7.97 7.68
∗ 7.22
∗
(3.32–9.32) (4.61–10.43) (3.25–10.56) (4.84–10.30) (3.21–8.53) (1.21–6.48) (6.01–9.81) (5.59–9.44) (5.21–9.32)
IL1 RA 494 611 676 335 710
∗ 996
∗ 497 517
† 510
†
(314–671) (307–812) (455–981) (221–472) (462–928) (703–1532) (285–672) (342–695) (342–714)
TNF 7.76 8.44 8.50 6.97 5.31
∗ 4.31
∗ 8.05 7.83
∗ 7.54
∗
(6.11–10.20) (6.72–11.28) (6.02–11.10) (1.12–11.01) (0.46–12.32) (1.04–7.94) (6.28–9.73) (5.99–9.62) (5.71–9.17)
TNF R1 1593 1719 1796 1497 1961
∗ 2367
∗ 1631 1736
† 1853
†
(1284–1902) (1273–2135) (1279–2387) (1212–1843) (1538–2985) (1759–3129) (1271–1961) (1329–2116) (1365–2362)
∗(P<. 01).
†(P>. 05).
signiﬁcant (P<. 01) rise in cytokine receptors/antagonists
levels at day 3 and 7 compared to baseline (Table 2).
Administration of doxycycline markedly enhanced this trend
so that by day 3 and 7, IL-1RA and TNF-R1 levels had
signiﬁcantly (P<. 01) increased when compared to day 0
levels in either the control or doxycycline treated groups. In
contrast, the administration of tetracycline did not aﬀect a
signiﬁcant (P>. 05) rise in either IL1-RA or TNF-R1 serum
concentrations at either day 3 or day 7 when compared to
controls (intergroup analysis). However, intragroup analysis
did show that tetracycline signiﬁcantly (P<. 05) increased
TNF-R1 levels at both day 0 and 7. No similar eﬀect was seen
for IL-1RA.
3.3. Diﬀerential Eﬀect of Doxycycline and Tetracycline on
Serum Cytokine and Cytokine Receptor/Antagonist Levels.
The above results indicated that both doxycycline and
tetracycline were eﬀective at modulating serum cytokine and
cytokine receptor/antagonist response in patients with DF
and DHF. However, in some instances, doxycycline appeared
to be more eﬀective. We, therefore, compared cytokine
levels in patients with DF and DHF after 3 and 7 days
of treatment (Table 3). Day 3 levels for proinﬂammatory
cytokines IL-1β and TNF-α and were signiﬁcantly lower in
patients with DF or DHF who received doxycycline versus
t e t r a c y c l i n e .I L - 6l e v e l sa td a y3w e r ec o m p a r a b l e( P>
.05) in patients treated with either drug. By day 7, IL-6
concentrations were signiﬁcantly (P<. 01) lower in the
group receiving doxycycline versus tetracycline. In patients
with DHF, doxycycline was signiﬁcantly more eﬀective at
lowering IL-6 levels at both days 3 and 7. A similar eﬀect
was seen for cytokine receptor/antagonist levels. Therefore,
administration of doxycycline signiﬁcantly raised IL1-RA
and TNF-R1 above those observed with tetracycline both at
day 3 and day 7.
4. Discussion
Elevatedcytokine levelsarea hallmarkof numerousbacterial
and viral infectious diseases including dengue [5, 7–9].4 Clinical and Developmental Immunology
Table 3: Diﬀerential eﬀect of Doxycycline and Tetracycline on cytokine levels and IL1-RA and S TNF-R1 in patients with dengue fever and
dengue hemorrhagic fever.
Dengue fever (GMT and ranges, pg/mL) DHF (GMT and ranges, pg/mL)
Doxycycline Tetracycline Doxycycline Tetracycline
Day 3 Day 7 Day 3 Day 7 Day 3 Day 7 Day 3 Day 7
IL-6 5.98† 3.96∗ 6.36 5.48 3.84∗ 2.36∗ 4.68 4.23
(3.70–7.98) (2.32–6.89) (4.72–7.90) (3.89–7.07) (2.01–6.73) (1.24–5.38) (2.93–6.98) (2.46–6.66)
IL-1β 2.29∗ 1.55∗ 3.36 2.23 5.32∗ 3.29∗ 7.68 7.22
(1.23–4.12) (1.10–2.78) (1.48–5.43) (1.02–4.69) (3.21–8.53) (1.21–6.48) (5.59–9.44) (5.21–9.32)
IL-1 RA 673∗ 964∗ 330 404 710∗ 996∗ 517 510
(486–851) (701–1459) (201–732) (231–920) (462–928) (703–1532) (342–695) (342–714)
TNF 2.42∗ 0.90∗ 3.89 3.31 5.31∗ 4.31∗ 7.83 7.54
(0.23–4.63) (0.4–3.02) (2.03–5.65) (1.19–5.08) (0.46–12.32) (1.04–7.94) (5.99–9.62) (5.71–9.17)
TNF R1 2432∗ 2616C 2115 2324 1961∗ 2367∗ 1736 1853
(673–3762) (1021–4412) (1358–3282) (1409–3974) (1538–2985) (1759–3129) (1329–2116) (1365–2362)
C(P<. 05).
∗(P<. 01).
†(P>. 05).
Proinﬂammatory cytokines, such as IL-6, IL1-β and TNF,
are believed to cause the majority of symptoms, such as
fever, malaise, and coagulopathies associated with infections.
Indeed, the degree of imbalance between such cytokines and
their anti-inﬂammatory counterparts may be the primary
prognostic indicator of disease outcome [19–21]. These
ﬁnding have led to the development of a broad spectrum
of potential therapeutic agents, including monoclonal anti-
bodies and antibiotics, which act to downregulate various
cytokines [22–25]. Drugs belonging to the tetracycline class
of antibiotics possess several advantages including a long
history of safe use and low cost. Additionally, their ability
to cross the blood-brain barrier with relative ease may
prove critical in the treatment of infections involving the
central nervous system. Atrasheuskaya et al. [5] have shown
that administration of tetracycline to patients with tick-
borne encephalitis aﬀected a marked positive shift in the
ratio of cytokines to their respective soluble receptors. Such
changes in cytokine to soluble receptor ratios appear to be
more critical to disease resolution than the absolute level of
cytokines themselves [26, 27].
In the present study, we investigate the eﬀectiveness
of tetracycline and doxycycline to modulate the levels of
various cytokines and soluble receptor/receptor antagonists
in patients with DF or DHF. As has been previously observed
[6–9],denguevirusinfectionresultedinamarkedincreasein
serumcytokineandcytokinereceptor/antagonistlevels.Both
drugs were able to modulate proinﬂammatory cytokines
levels. Downregulation was rapid, being observed within 3
days of treatment and continuing through day 7. A similar
eﬀect was noted for IL-1RA but not for TNF-R1. In patients
with DF, TNF-R1 levels were not statistically diﬀerent when
control patients were compared to either treatment group.
An intragroup analysis did achieve signiﬁcance indicating
that diﬀerences in baseline levels between groups at the time
therapy was initiated may have a substantial inﬂuence. In
the case of DHF, doxycycline showed a clear superiority to
tetracycline in modulating TNF-R1 concentration. A direct
comparison between tetracycline and doxycycline demon-
strated that the later was a far more eﬀective immunomod-
ulator. This can most likely be attributed to the fact that
doxycycline has a longer plasma half-life than tetracycline.
Both drugs appeared to exert the same degree of eﬀectiveness
in patients with DF or DHF, a much more severe disease
syndrome.
An additional potential beneﬁt to using doxycycline in
the treatment of DF or DHF is its recently discovered ability
to inhibit dengue virus multiplication in tissue culture [28].
Doxycycline, but not tetracycline, was able to interact with
the dengue virus E protein to inhibit a conformational
change which is an essential step in the process by which the
virus enters susceptible cells.
The present study indicates that doxycycline may provide
a clinical beneﬁt in the treatment of dengue virus infection
bymodulatingthecytokinecascade.Unfortunately,thestudy
design did not allow for us to determine this. We hope to
initiate a study in the near future to determine if doxycycline
can provide a clinical beneﬁt to patients with DF or DHF
by monitoring disease severity, mortality rates, and time of
hospital discharge postenrollment.
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